version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals’ websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have
increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the …

… Pedersen has received honoraria grants and/or served on the speakers’ bureaus of
AstraZeneca Pharma US, Inc., Merck Sharp & Dohme Corporation, Pfizer Inc., and Roche …

Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by …

Background Trials of statin therapy have had conflicting findings on the risk of development
of diabetes mellitus in patients given statins. We aimed to establish by a meta-analysis of …

… Financial Disclosures: Dr Pedersen has received consultation fees and speaker’s honoraria
from Pfizer, Merck, Merck AG, and AstraZeneca and research grants and steering committee …

OBJECTIVE To assess in diabetic patients with coronary heart disease (CHD) the effect of
cholesterol lowering with simvastatin on mortality and the risk of CHD and other …

Background Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic
valve, but lipid-lowering studies have had conflicting results. Methods We conducted a …

ContextLimited data are available evaluating how the timing and intensity of statin therapy
following an acute coronary syndrome (ACS) event affect clinical outcome.ObjectiveTo …

… Dr Pedersen reported receiving speakers' honoraria from and consulting for Pfizer and
Merck-Schering Plough and receiving speakers' honoraria from AstraZeneca. Dr Tikkanen …